US 7,390,482 B2
	Drug for auditory dysfunction
Yasufumi Kaneda, Minoh (Japan); Kazuo Oshima, Minoh (Japan); Ryuichi Morishita, Osaka (Japan); and Takeshi Kubo, Kobe (Japan)
Assigned to Anges MG, Inc., Ibaraki-shi, Osaka (Japan)
Appl. No. 10/527,195 PCT Filed Oct. 02, 2003, PCT No. PCT/JP03/12674 § 371(c)(1), (2), (4) Date Mar. 10, 2005, PCT Pub. No. WO2004/030702, PCT Pub. Date Apr. 15, 2004.
Claims priority of application No. 2002-289639 (JP), filed on Oct. 02, 2002.
Prior Publication US 2006/0233755 A1, Oct. 19, 2006
Int. Cl. A01N 63/00 (2006.01); A01N 65/00 (2006.01); A01N 43/04 (2006.01)

U.S. Cl. 424—93.2  [424/93.1; 514/44]

2 Claims

1. A method of treating hearing impairment, which comprises intrathecally administering a plasmid encoding hepatocyte growth factor (HGF) encapsulated in an inactivated hemagglutinating virus of Japan (HVJ) particle to a patient with hearing impairment.